Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma who have received at least four lines of therapy.